Treatment with VE-cadherin mAbs inhibits growth of H5V hemangiomas.
Hemangiomas were established by injecting 1 × 105H5V cells subcutaneously into the right flank of nu/nu (CD-1)BR mice. The day after injection and every 3 days, mice received equal amounts of BV14 or BV13 (50 μg/mouse), or DC101 (800 μg/mouse), or the combination of BV14 and DC101 (50 μg/mouse and 800 μg/mouse, respectively). Control mice were treated with 50 μg/mouse of nonimmune rat IgG. Tumor size was measured every 3 days. (A) Representative hemangiomas in mice treated with nonimmune IgG, BV13, or BV14 at 19 days after implantation. In animals treated with either BV13 or BV14, the size of tumors was significantly smaller. Note the presence of hematomas around the tumor upon BV13 treatment, indicating local increase in permeability. (B) Hemangioma growth in mice treated with different mAbs. BV13 and BV14 inhibited tumor progression, while DC101 was ineffective. Combination of BV14 with DC101 was more effective. Data are means of 3 separate experiments performed in quintuplicate. SEM never exceeded 20% of the means. Similar results were obtained when the dose of BV14 was increased to 200 μg/mouse.
